UCB’s anti-tau Alzheimer’s program fails Phase 2 primary endpoint, but highlights positive secondaries

UCB reported Thursday that a Phase 2 study for its anti-tau Alzheimer’s program bepranemab did not meet its primary endpoint.

Neither the low dose nor …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

New UCL hub to advance cancer detection with imaging tech

UCL will lead a £17 million surgical imaging hub to improve cancer detection and take part in a £12 million collaboration to help solve age

October 8, 2024

Here’s Why These Cannabis ETFs Aren’t Very Good

You’re reading a copy of this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter

August 27, 2023

AstraZeneca receives positive NICE recommendations for lung cancer treatment

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of

January 25, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.